-
Mashup Score: 0
The study reveals a ‘tug-of-war’ in the brain between two key learning systems.
Source: www.jewishpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 16TYK2 regulates tau levels, phosphorylation and aggregation in a tauopathy mouse model - 2 month(s) ago
Nature Neuroscience – Tyrosine kinase 2 (TYK2) critically regulates tau levels and aggregation by phosphorylating tau’s tyrosine 29. Partial inhibition of TYK2 mitigates tau pathologies in…
Source: www.nature.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 16A potential method for interrupting the misfolding of tau protein that underlies neurodegenerative disease - 9 month(s) ago
A spectrum of neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are due to the accumulation of abnormal, misfolded …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 11Structural and functional damage to neuronal nuclei caused by extracellular tau oligomers - 1 year(s) ago
INTRODUCTION Neuronal nuclei are normally smoothly surfaced. In Alzheimer’s disease (AD) and other tauopathies, though, they often develop invaginations. We investigated mechanisms and functional co…
Categories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Labcorp Launches New Amyloid-Tau-Neurodegeneration Biomarker Blood Test - Practical Neurology - 1 year(s) ago
Labcorp has announced that its ATN Profile (Laboratory Corporation of America Holdings, Burlington, NC) test for identifying and assessing biological
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Diagnostic criteria for Alzheimer’s disease were revised only five years ago, but the field has learned a lot since then. At the Alzheimer’s Association International Conference, held last month in Amsterdam, Clifford Jack of the Mayo Clinic in Rochester, Minnesota, proposed updates to the current “ATN” system. Like the 2018 criteria, the new ones are the product of a joint National Institute on Aging-Alzheimer’s Association working group Jack leads. The draft criteria take into account recent discoveries
Source: www.alzforum.orgCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Tau-PET : a window into the future of Alzheimer’s patients - 1 year(s) ago
Alzheimer’s disease, one of the most common neurodegenerative diseases, leads to progressive loss of memory and autonomy. It is characterised by the accumulation of neurotoxic proteins in the brain, namely amyloid plaques and tau tangles. Due to the silent development of pathology over decades, very early diagnosis is of utmost importance to be able to take action as early as possible in the disease process. A team from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) has demonstrated that tau PET – a novel imaging technique for visualising the tau protein – can predict cognitive decline in patients much better than the imaging techniques normally used. These results, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, argue in favour of the rapid introduction of tau PET into the clinical routine to provide patients with early and individualised solutions.
Source: www.eurekalert.orgCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 14The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline - 1 year(s) ago
INTRODUCTION Tau and neurodegeneration strongly correlate with cognitive impairment, as compared to amyloid. However, their contribution in explaining cognition and predicting cognitive decline in m…
Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 5How Coffee Could Protect Against Alzheimer's: Espresso Found To Inhibit Tau Proteins - 1 year(s) ago
Compounds extracted from a regular espresso prevented the aggregation of tau proteins.
Source: www.iflscience.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 4Trial of Donanemab in Early Symptomatic Alzheimer Disease - 1 year(s) ago
This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.
Source: jamanetwork.comCategories: Expert Picks, Latest HeadlinesTweet
#TAU Groundbreaking Discovery Illuminates the Brain’s ‘Memory Wars’ https://t.co/iAjd6tkqMO via @JewishPress